Notably, our analysis identified TREX1 as a critical determinant of poor clinical outcome; TREX1 is significantly overexpressed in prostate tumor tissues, and its knockdown markedly inhibits prostate cancer cell proliferation, migration, and invasion in vitro. This evidence concerns the gene TREX1 and prostate carcinoma.